REPORT ID 3309

Global Live Attenuated Vaccine Sales Market Report 2017

Publish Date
13-Dec-17
Pages
103
Format
Electronic (PDF)

In this report, the global Live Attenuated Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Live Attenuated Vaccine for these regions, from 2012 to 2022 (forecast), covering
    United States
    China
    Europe
    Japan
    Southeast Asia
    India

Global Live Attenuated Vaccine market competition by top manufacturers/players, with Live Attenuated Vaccine sales volume, Price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Astellas Pharma (Japan)
    CSL Limited (Australia)
    Emergent BioSolutions (U.S.)
    GlaxoSmithKline (U.K.)
    Johnson & Johnson (U.S.)
    MedImmune (U.S.)
    Merck & Co (U.S.)
    Pfizer (U.S.)
    Sanofi Pasteur (France)
    Serum Institute of India Pvt (India)
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    By End User
        Pediatrics
        Adults
    By Disease Indication
        Pneumococcal
        Influenza
        HPV
        Hepatitis
        Rotavirus
        DTP
        Polio
        MMR
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Live Attenuated Vaccine Sales Market Report 2017
1 Live Attenuated Vaccine Market Overview
    1.1 Product Overview and Scope of Live Attenuated Vaccine
    1.2 Classification of Live Attenuated Vaccine by Product Category
        1.2.1 Global Live Attenuated Vaccine Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 Global Live Attenuated Vaccine Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Pediatrics
        1.2.4 Adults
    1.3 Global Live Attenuated Vaccine Market by Application/End Users
        1.3.1 Global Live Attenuated Vaccine Sales (Volume) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Medical Center
        1.3.4 Others
    1.4 Global Live Attenuated Vaccine Market by Region
        1.4.1 Global Live Attenuated Vaccine Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 United States Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.3 China Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.4 Europe Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.5 Japan Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.7 India Live Attenuated Vaccine Status and Prospect (2012-2022)
    1.5 Global Market Size (Value and Volume) of Live Attenuated Vaccine (2012-2022)
        1.5.1 Global Live Attenuated Vaccine Sales and Growth Rate (2012-2022)
        1.5.2 Global Live Attenuated Vaccine Revenue and Growth Rate (2012-2022)

2 Global Live Attenuated Vaccine Competition by Players/Suppliers, Type and Application
     2.1 Global Live Attenuated Vaccine Market Competition by Players/Suppliers
        2.1.1 Global Live Attenuated Vaccine Sales and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Global Live Attenuated Vaccine Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Global Live Attenuated Vaccine (Volume and Value) by Type
        2.2.1 Global Live Attenuated Vaccine Sales and Market Share by Type (2012-2017)
        2.2.2 Global Live Attenuated Vaccine Revenue and Market Share by Type (2012-2017)
    2.3 Global Live Attenuated Vaccine (Volume and Value) by Region
        2.3.1 Global Live Attenuated Vaccine Sales and Market Share by Region (2012-2017)
        2.3.2 Global Live Attenuated Vaccine Revenue and Market Share by Region (2012-2017)
    2.4 Global Live Attenuated Vaccine (Volume) by Application

3 United States Live Attenuated Vaccine (Volume, Value and Sales Price)
    3.1 United States Live Attenuated Vaccine Sales and Value (2012-2017)
        3.1.1 United States Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
        3.1.2 United States Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
        3.1.3 United States Live Attenuated Vaccine Sales Price Trend (2012-2017)
    3.2 United States Live Attenuated Vaccine Sales Volume and Market Share by Players
    3.3 United States Live Attenuated Vaccine Sales Volume and Market Share by Type
    3.4 United States Live Attenuated Vaccine Sales Volume and Market Share by Application

4 China Live Attenuated Vaccine (Volume, Value and Sales Price)
    4.1 China Live Attenuated Vaccine Sales and Value (2012-2017)
        4.1.1 China Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
        4.1.2 China Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
        4.1.3 China Live Attenuated Vaccine Sales Price Trend (2012-2017)
    4.2 China Live Attenuated Vaccine Sales Volume and Market Share by Players
    4.3 China Live Attenuated Vaccine Sales Volume and Market Share by Type
    4.4 China Live Attenuated Vaccine Sales Volume and Market Share by Application

5 Europe Live Attenuated Vaccine (Volume, Value and Sales Price)
    5.1 Europe Live Attenuated Vaccine Sales and Value (2012-2017)
        5.1.1 Europe Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
        5.1.2 Europe Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
        5.1.3 Europe Live Attenuated Vaccine Sales Price Trend (2012-2017)
    5.2 Europe Live Attenuated Vaccine Sales Volume and Market Share by Players
    5.3 Europe Live Attenuated Vaccine Sales Volume and Market Share by Type
    5.4 Europe Live Attenuated Vaccine Sales Volume and Market Share by Application

6 Japan Live Attenuated Vaccine (Volume, Value and Sales Price)
    6.1 Japan Live Attenuated Vaccine Sales and Value (2012-2017)
        6.1.1 Japan Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
        6.1.2 Japan Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
        6.1.3 Japan Live Attenuated Vaccine Sales Price Trend (2012-2017)
    6.2 Japan Live Attenuated Vaccine Sales Volume and Market Share by Players
    6.3 Japan Live Attenuated Vaccine Sales Volume and Market Share by Type
    6.4 Japan Live Attenuated Vaccine Sales Volume and Market Share by Application

7 Southeast Asia Live Attenuated Vaccine (Volume, Value and Sales Price)
    7.1 Southeast Asia Live Attenuated Vaccine Sales and Value (2012-2017)
        7.1.1 Southeast Asia Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
        7.1.2 Southeast Asia Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
        7.1.3 Southeast Asia Live Attenuated Vaccine Sales Price Trend (2012-2017)
    7.2 Southeast Asia Live Attenuated Vaccine Sales Volume and Market Share by Players
    7.3 Southeast Asia Live Attenuated Vaccine Sales Volume and Market Share by Type
    7.4 Southeast Asia Live Attenuated Vaccine Sales Volume and Market Share by Application

8 India Live Attenuated Vaccine (Volume, Value and Sales Price)
    8.1 India Live Attenuated Vaccine Sales and Value (2012-2017)
        8.1.1 India Live Attenuated Vaccine Sales and Growth Rate (2012-2017)
        8.1.2 India Live Attenuated Vaccine Revenue and Growth Rate (2012-2017)
        8.1.3 India Live Attenuated Vaccine Sales Price Trend (2012-2017)
    8.2 India Live Attenuated Vaccine Sales Volume and Market Share by Players
    8.3 India Live Attenuated Vaccine Sales Volume and Market Share by Type
    8.4 India Live Attenuated Vaccine Sales Volume and Market Share by Application

9 Global Live Attenuated Vaccine Players/Suppliers Profiles and Sales Data
    9.1 Astellas Pharma (Japan)
        9.1.1 Company Basic Information, Manufacturing Base and Competitors
        9.1.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.1.2.1 Product A
            9.1.2.2 Product B
        9.1.3 Astellas Pharma (Japan) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.1.4 Main Business/Business Overview
    9.2 CSL Limited (Australia)
        9.2.1 Company Basic Information, Manufacturing Base and Competitors
        9.2.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.2.2.1 Product A
            9.2.2.2 Product B
        9.2.3 CSL Limited (Australia) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.2.4 Main Business/Business Overview
    9.3 Emergent BioSolutions (U.S.)
        9.3.1 Company Basic Information, Manufacturing Base and Competitors
        9.3.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.3.2.1 Product A
            9.3.2.2 Product B
        9.3.3 Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.3.4 Main Business/Business Overview
    9.4 GlaxoSmithKline (U.K.)
        9.4.1 Company Basic Information, Manufacturing Base and Competitors
        9.4.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.4.2.1 Product A
            9.4.2.2 Product B
        9.4.3 GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.4.4 Main Business/Business Overview
    9.5 Johnson & Johnson (U.S.)
        9.5.1 Company Basic Information, Manufacturing Base and Competitors
        9.5.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.5.2.1 Product A
            9.5.2.2 Product B
        9.5.3 Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.5.4 Main Business/Business Overview
    9.6 MedImmune (U.S.)
        9.6.1 Company Basic Information, Manufacturing Base and Competitors
        9.6.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.6.2.1 Product A
            9.6.2.2 Product B
        9.6.3 MedImmune (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.6.4 Main Business/Business Overview
    9.7 Merck & Co (U.S.)
        9.7.1 Company Basic Information, Manufacturing Base and Competitors
        9.7.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.7.2.1 Product A
            9.7.2.2 Product B
        9.7.3 Merck & Co (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.7.4 Main Business/Business Overview
    9.8 Pfizer (U.S.)
        9.8.1 Company Basic Information, Manufacturing Base and Competitors
        9.8.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.8.2.1 Product A
            9.8.2.2 Product B
        9.8.3 Pfizer (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.8.4 Main Business/Business Overview
    9.9 Sanofi Pasteur (France)
        9.9.1 Company Basic Information, Manufacturing Base and Competitors
        9.9.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.9.2.1 Product A
            9.9.2.2 Product B
        9.9.3 Sanofi Pasteur (France) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.9.4 Main Business/Business Overview
    9.10 Serum Institute of India Pvt (India)
        9.10.1 Company Basic Information, Manufacturing Base and Competitors
        9.10.2 Live Attenuated Vaccine Product Category, Application and Specification
            9.10.2.1 Product A
            9.10.2.2 Product B
        9.10.3 Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        9.10.4 Main Business/Business Overview

10 Live Attenuated Vaccine Maufacturing Cost Analysis
    10.1 Live Attenuated Vaccine Key Raw Materials Analysis
        10.1.1 Key Raw Materials
        10.1.2 Price Trend of Key Raw Materials
        10.1.3 Key Suppliers of Raw Materials
        10.1.4 Market Concentration Rate of Raw Materials
    10.2 Proportion of Manufacturing Cost Structure
        10.2.1 Raw Materials
        10.2.2 Labor Cost
        10.2.3 Manufacturing Process Analysis of Live Attenuated Vaccine
    10.3 Manufacturing Process Analysis of Live Attenuated Vaccine

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
    11.1 Live Attenuated Vaccine Industrial Chain Analysis
    11.2 Upstream Raw Materials Sourcing
    11.3 Raw Materials Sources of Live Attenuated Vaccine Major Manufacturers in 2016
    11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
    12.1 Marketing Channel
        12.1.1 Direct Marketing
        12.1.2 Indirect Marketing
        12.1.3 Marketing Channel Development Trend
    12.2 Market Positioning
        12.2.1 Pricing Strategy
        12.2.2 Brand Strategy
        12.2.3 Target Client
    12.3 Distributors/Traders List

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes Threat
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs/Customer Preference Change
    13.3 Economic/Political Environmental Change

14 Global Live Attenuated Vaccine Market Forecast (2017-2022)
    14.1 Global Live Attenuated Vaccine Sales Volume, Revenue and Price Forecast (2017-2022)
       14.1.1 Global Live Attenuated Vaccine Sales Volume and Growth Rate Forecast (2017-2022)
       14.1.2 Global Live Attenuated Vaccine Revenue and Growth Rate Forecast (2017-2022)
       14.1.3 Global Live Attenuated Vaccine Price and Trend Forecast (2017-2022)
    14.2 Global Live Attenuated Vaccine Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
       14.2.1 Global Live Attenuated Vaccine Sales Volume and Growth Rate Forecast by Regions (2017-2022)
       14.2.2 Global Live Attenuated Vaccine Revenue and Growth Rate Forecast by Regions (2017-2022)
       14.2.3 United States Live Attenuated Vaccine Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.4 China Live Attenuated Vaccine Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.5 Europe Live Attenuated Vaccine Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.6 Japan Live Attenuated Vaccine Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.7 Southeast Asia Live Attenuated Vaccine Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.8 India Live Attenuated Vaccine Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
    14.3 Global Live Attenuated Vaccine Sales Volume, Revenue and Price Forecast by Type (2017-2022)
       14.3.1 Global Live Attenuated Vaccine Sales Forecast by Type (2017-2022)
       14.3.2 Global Live Attenuated Vaccine Revenue Forecast by Type (2017-2022)
       14.3.3 Global Live Attenuated Vaccine Price Forecast by Type (2017-2022)
    14.4 Global Live Attenuated Vaccine Sales Volume Forecast by Application (2017-2022)

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology/Research Approach
        16.1.1 Research Programs/Design
        16.1.2 Market Size Estimation
        16.1.3 Market Breakdown and Data Triangulation
    16.2 Data Source
        16.2.1 Secondary Sources
        16.2.2 Primary Sources
    16.3 Disclaimer